Arnon Nagler1,2, Myriam Labopin1,3,4,5, Dietrich Beelen6, Fabio Ciceri7, Liisa Volin8, Avichai Shimoni2, Roberto Foá9, Noel Milpied10, Jacopo Peccatori7, Emmanuelle Polge1, Audrey Mailhol1, Mohamad Mohty1,3,4,5, Bipin N Savani1,11. 1. Acute Leukemia Working Party, European Society for Blood and Marrow Transplantation Paris Study Office/European Center for Biostatistical and Epidemiological Evaluation in Hematopoietic Cell Therapy (CEREST-TC), Paris, France. 2. Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel. 3. Department of Hematology, St. Antoine Hospital, Paris, France. 4. INSERM UMR 938, Paris, France. 5. Pierre and Marie Curie University, Paris, France. 6. Department of Bone Marrow Transplantation, University Hospital, Essen, Germany. 7. Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy. 8. Stem Cell Transplantation Unit, Comprehensive Cancer Center, Helsinki University Central Hospital, Helsinki, Finland. 9. Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. 10. CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France. 11. Long-Term Transplantation Clinic, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia (AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival. In recent years, new conditioning regimens have been explored to improve transplantation outcomes in patients with AML. Treosulfan combines a potent immunosuppressive and antileukemic effect with a low toxicity profile. METHODS: To investigate the role of treosulfan-based conditioning, the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party performed a registry analysis of 520 adult patients with AML who received treosulfan-based conditioning and underwent HCT between 2000 and 2012, including 225 patients in first complete remission, 107 in second or later complete remission, and 188 with active/advanced disease 188 (88 with primary refractory disease). The median patient age was 57 years (range, 20-73 years). Donors were human leukocyte antigen-identical siblings (n = 187), unrelated donors (n = 235), or mismatched related donors (n = 98). Conditioning regimens included treosulfan (42 g/m2 [n = 396], 36 g/m2 [n = 109], or 30 g/ m2 [n = 15]) with fludarabine or alkylating agents followed by infusion of hematopoietic stem cells (bone marrow, n = 52; peripheral blood, n = 468). RESULTS: At a median follow-up of 61 months, the 5-year overall survival, leukemia-free survival, relapse incidence, and nonrelapse mortality rates were 38%, 33%, 42%, and 25%, respectively. The incidence of grade II-IV acute and chronic graft-versus-host disease was 24% (grade III-V, 11%) and 38%, respectively. Only 11 patients (2%) developed veno-occlusive disease, with two deaths (0.4%) from veno-occlusive disease. CONCLUSIONS: Treosulfan-based conditioning regimens provide an acceptable long-term survival with favorable nonrelapse mortality and a very low risk of veno-occlusive disease. Further studies are needed to optimize the treosulfan-based conditioning regimen for patients with AML. Cancer 2017;123:2671-79.
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia (AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival. In recent years, new conditioning regimens have been explored to improve transplantation outcomes in patients with AML. Treosulfan combines a potent immunosuppressive and antileukemic effect with a low toxicity profile. METHODS: To investigate the role of treosulfan-based conditioning, the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party performed a registry analysis of 520 adult patients with AML who received treosulfan-based conditioning and underwent HCT between 2000 and 2012, including 225 patients in first complete remission, 107 in second or later complete remission, and 188 with active/advanced disease 188 (88 with primary refractory disease). The median patient age was 57 years (range, 20-73 years). Donors were human leukocyte antigen-identical siblings (n = 187), unrelated donors (n = 235), or mismatched related donors (n = 98). Conditioning regimens included treosulfan (42 g/m2 [n = 396], 36 g/m2 [n = 109], or 30 g/ m2 [n = 15]) with fludarabine or alkylating agents followed by infusion of hematopoietic stem cells (bone marrow, n = 52; peripheral blood, n = 468). RESULTS: At a median follow-up of 61 months, the 5-year overall survival, leukemia-free survival, relapse incidence, and nonrelapse mortality rates were 38%, 33%, 42%, and 25%, respectively. The incidence of grade II-IV acute and chronic graft-versus-host disease was 24% (grade III-V, 11%) and 38%, respectively. Only 11 patients (2%) developed veno-occlusive disease, with two deaths (0.4%) from veno-occlusive disease. CONCLUSIONS:Treosulfan-based conditioning regimens provide an acceptable long-term survival with favorable nonrelapse mortality and a very low risk of veno-occlusive disease. Further studies are needed to optimize the treosulfan-based conditioning regimen for patients with AML. Cancer 2017;123:2671-79.
Authors: Michał Romański; Anna Zacharzewska; Artur Teżyk; Franciszek K Główka Journal: Eur J Drug Metab Pharmacokinet Date: 2018-10 Impact factor: 2.441
Authors: Krzysztof Kalwak; Monika Mielcarek; Katharine Patrick; Jan Styczynski; Peter Bader; Selim Corbacioglu; Birgit Burkhardt; Karl Walter Sykora; Katarzyna Drabko; Jolanta Gozdzik; Franca Fagioli; Johann Greil; Bernd Gruhn; Rita Beier; Franco Locatelli; Ingo Müller; Paul Gerhardt Schlegel; Petr Sedlacek; Klaus Daniel Stachel; Claudia Hemmelmann; Ann-Kristin Möller; Joachim Baumgart; Ajay Vora Journal: Bone Marrow Transplant Date: 2020-03-20 Impact factor: 5.483
Authors: Khalil Ben Hassine; Madeleine Powys; Peter Svec; Miroslava Pozdechova; Birgitta Versluys; Marc Ansari; Peter J Shaw Journal: Front Pediatr Date: 2021-12-10 Impact factor: 3.418